Project
Abbvie M16-852 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and
Automatically Closed ยท 2019 until 2024
Rubbert-Roth Andrea, Hutz Carina Liane, Bartz-Batliner Mira, Neumann Thomas, Peischl Riana, Sasselli Clelia
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2019
End Date
2024
Financing
Industry
Study Design
Study M16-852 is a Phase 3, global, multicenter, randomized, double-blind, PBO-controlled study.
Approximately 420 subjects will be enrolled into this study.
Keywords
active GCA, upadacitinib
Brief description/objective
Giant Cell Arteritis: Phase 3 Safety and Efficacy Study of Upadacitinib in
Subjects with Giant Cell Arteritis